Yoon J, Lee DG, Song H et al (2024) Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced -arrestin recruitment and sustained glycemic control for type 2 diabetes
It works by reducing appetite, slowing gastric emptying, and improving insulin response when combined with lifestyle modification under medical supervision
In addition to HSCs, in an injured liver, hepatocytes and bile duct cells can also transform into fibroblasts via the process of epithelialmesenchymal transition (EMT), and excessive extracellular matrix (ECM) deposition by fibroblasts contributes to liver fibrosis
Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns
Improved insulin response pancreatic beta cells release insulin more efficiently after meals, supporting steadier blood glucose levels and reducing the fat-storage signals driven by insulin spikes
This includes considering any pre-existing health conditions, such as pancreatic issues, a history of gallbladder problems, or diabetic retinopathy, which may influence the safety and efficacy of the medication